<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT943-11717</title>
	</head>
	<body>
		<main>
			<p>940728 FT  28 JUL 94 / UK Company News: SmithKline Beecham awaits committee's decision The US Food and Drug Administration advisory committee for over-the-counter medicines yesterday failed to decide whether to recommend Tagamet - SmithKline Beecham's top-selling product last year - for approval. The Anglo-American healthcare group wants to be able to sell the anti-ulcer drug, whose US patents expired in May, without a prescription in pharmacies. The medicine would be used for heartburn The committee is scheduled to meet again this morning to see if it can make a recommendation. The main concerns expressed by committee members were the drug's possible interactions with other medicines, in particular asthma treatments and products for thinning the blood. SmithKline Beecham presented altered labelling and revised data on Tagamet's safety and efficacy. In September last year, the committee had asked for additional data.</p>
		</main>
</body></html>
            